Structure Therapeutics Inc. (GPCR)
GPCRNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$21.33
-0.0810 (-0.38%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $1.55bn
- P/E
- –
- EPS, last 4 quarters
- $-1.99
- Dividend yield
- –
- Day range
- –
- 52-week range
- $18.70 to $94.90
- Average volume
- 1.25m
- Previous close
- $21.41
Analysts
12 coveringBuy12 buy, 0 hold, 0 sell
Targets a year out average $98.50, +361.8% from here
Earnings
next estimate $-0.5100Next report
Dec 2025
-40.0%
Mar 2026
+10.3%
Jun 2026
-25.6%
Sep 2026
-29.4%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$73.79m | $13.74m | -$89.38m | -$118.63m |
| Net income | -$65.71m | $33.00m | -$75.97m | -$106.16m |
News
8 latest- Structure Q3 Loss Widens On Higher R&D Costs; Three Aleniglipron Readouts Due In Q4 RTTNews · 15 hours ago
- Structure Therapeutics Reports Third Quarter 2026 Financial ResultsFintel · 1 day ago
- Novo Up 4% in a Month: How Should Investors Approach the Stock Now?Zacks · 1 day ago
- Novo Before Q3 Earnings: How Should Investors Play the Stock?Zacks · Nov 2, 2026
- Buy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 EarningsZacks · Oct 27, 2026
- How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?Zacks · Oct 21, 2026
- How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?Zacks · Oct 19, 2026
- Novo Down 11% in a Month: How Should Investors Approach the Stock Now?Zacks · Oct 12, 2026
The company
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- structuretx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.